Implications of abnormal glucose metabolism in patients with coronary artery disease

Diabetes and Vascular Disease Research

Volumn 5, Issue 4, 2008, Pages 285-290

  Anselmino, Matteo ^a   Wallander, Märit ^a   Norhammar, Anna ^a   Mellbin, Linda ^a   Rydén, Lars ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular events; Coronary artery disease; Diabetes mellitus; Impaired glucose regulation; Prediabetes; Prevention; Prognosis

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GLARGINE; SOMATOMEDIN BINDING PROTEIN 1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; FLATULENCE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; GLUCOSE METABOLISM DISORDERS; HYPOGLYCEMIC AGENTS; PATIENT CARE TEAM; PREDIABETIC STATE; TREATMENT OUTCOME;

EID: 56249090047     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.041     Document Type: Review

References (38)

1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-31.
2. Boyle JP, Honeycutt AA, Narayan VKM et al. Projection of diabetes burden through 2050. Diabetes Care 2001;24:1936-40.
3. Clark C, Perry R. Type 2 diabetes and macrovascular disease. Epidemiology and etiology. Am Heart J 1999;138:S330-S333.
4. Wylie G, Hungin AP, Neely J. Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions. BMJ 2002;324:1190.
5. Whitford DL, Lamont SS, Crosland A. Screening for type 2 diabetes: is it worthwhile? Views of general practitioners and practice nurses. Diabet Med 2003;20:155-8.
6. Wolever TM, Chiasson JL, Csima A et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336-40.
7. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-21.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30:S42-S47.
9. Bartnik M, Rydén L, Malmberg K et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007; 93:72-7.
10. DECODA Study Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals - an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). Diabet Med 2002;19:549-57.
11. DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
12. Qiao Q, Pyorala K, Pyorala M et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23:1267-75.
13. Wallander M, Malmberg K, Rydén L, Norhammar A, Tenerz Å. Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 2008;3:36-8.
14. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
15. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:2140-4.
16. Bartnik M, Rydén L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25: 1880-90.
17. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15:815-19.
18. Hu D, Pan CY, Yu J. The relationship between coronary artery disease and abnormal glucose regulation in China - The China Heart Survey. Eur Heart J 2006;27:2573-9.
19. Norhammar A, Malmberg K, Diderholm E et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004;43:585-91.
20. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-7.
21. Jarret RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976; 2:1009-12.
22. Fuller JH, Shipley MJ, Rose G et al. Coronary heart disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1:1373-6.
23. Rodriguez BL, Lau N, Bruchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu Heart Program. Diabetes Care 1999;22:1262-5.
24. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care 1998; 21:360-7.
25. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
26. Lenzen M, Rydén L, Ohrvik J et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006;27: 2969-74.
27. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
28. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-44.
29. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 2004; 25:153-75.
30. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K. Insulin-like growth factor binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007;30:2343-8.
31. Wallander M, Söderberg S, Norhammar A. Leptin - a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and no previously known type 2 diabetes. Diabet Med 2008; 25:949-55.
32. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-94.
33. Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25:10-16.
34. Anselmino M, Öhrvik J, Malmberg K et al. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008;29:177-84.
35. The ORIGIN Trial Investigators. Rationale, design and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155: 26-32.
36. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
37. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
38. Anselmino M, Malmberg K, Öhrvik J, Ryden L. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease. A report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rebabil 2008;15:216-23.